Skip to content

Transcranial Direct Current Stimulation (tDCS) and Cognitive Task in Depression

Pilot Study of Transcranial Direct Current Stimulation (tDCS) and Cognitive Task in Depression.

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02296437
Acronym
tDCS + CT
Enrollment
40
Registered
2014-11-20
Start date
2014-11-30
Completion date
Unknown
Last updated
2017-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

Among antidepressant treatments, electroconvulsive therapy (ECT) remains the most effective. However, patient concerns with cognitive side effects have encouraged trials of new, non-convulsive forms of mild brain stimulation such as transcranial Direct Current Stimulation (tDCS). Our past and present studies of tDCS suggest that it has antidepressant effects and is safe, painless and well tolerated. However, not all patients may have an adequate response, raising the need to find ways of optimising efficacy. This clinical pilot study will examine the feasibility and safety of combining tDCS with a cognitive training task which engages the same brain region targeted by tDCS for treatment of depression.

Interventions

Sponsors

Icahn School of Medicine at Mount Sinai
CollaboratorOTHER
The University of New South Wales
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Participants are aged 18-65 years. 2. Participant meets criteria for a DSM-V Major Depressive episode. Criteria are as follows: Five or more symptoms present during the same 2-week period, including either 1 or 2: 1) depressed mood, 2) loss of interest or pleasure, 3) significant weight loss or gain, 4) insomnia or hypersomnia, 5) psychomotor agitation or retardation, 6) fatigue or loss of energy, 7) feelings of worthlessness or excessive or inappropriate guilt, 8) diminished ability to think concentrate or make decisions, and 9) recurrent thoughts of death, recurrent suicidal ideation, suicide attempt or plan. 3. MADRS score of 20 or more. 4. Right handed 5. A history of non-response to ≥ 2 adequate trials of antidepressant medication treatment.

Exclusion criteria

1. DSM-V psychotic disorder. 2. Drug or alcohol abuse or dependence (preceding 6 months). 3. Inadequate response to ECT (current episode of depression). 4. Regular benzodiazepine medication 5. Rapid clinical response required, e.g., due to high suicide risk. 6. Clinically defined neurological disorder or insult. 7. Metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites. 8. Pregnancy.

Design outcomes

Primary

MeasureTime frame
Montgomery and Asberg Depression Rating Scale (MADRS)6 weeks

Countries

Australia

Contacts

Primary ContactDonel Martin, PhD
donel.martin@unsw.edu.au61 2 9382 8353

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026